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Synthesis of functionalised 4H-quinolizin-4-ones via
tandem Horner–Wadsworth–Emmons oleﬁnation/
cyclisation†
Calum W. Muir,a Alan R. Kennedy,a Joanna M. Redmondb and Allan J. B. Watson*a
4H-Quinolizin-4-ones are a unique class of heterocycle with valuable physicochemical properties and
which are emerging as key pharmacophores for a range of biological targets. A tandem Horner–Wads-
worth–Emmons oleﬁnation/cyclisation method has been developed to allow facile access to substituted
4H-quinolizin-4-ones encoded with a range of functional groups.
Heterocyclic compounds are of particular interest and signifi-
cant importance in the search for new bioactive agents in both
the agrochemical and pharmaceutical industries. Indeed, with
particular reference to the pharmaceutical industry, hetero-
cyclic motifs are especially prevalent with over 60% of the top
retailing drugs containing at least one heterocyclic nucleus as
part of the overall topography of the compound.1
In this regard, heteroaromatic rings are extensively used as
scaﬀolds as (i) their structure and associated physicochemical
properties often lead to eﬃcient binding to a biological target
and selectivity, (ii) derivatives are often readily available via
common synthetic transformations, (iii) there are no compli-
cations due to stereochemistry, and (iv) a novel ring system or
substitution pattern of an existing system can expand the intel-
lectual property estate of a discovery programme.2 Conse-
quently, the identification of new heteroaromatic rings that (i)
exhibit improved properties over existing frameworks (e.g.,
improved metabolic stability, higher solubility, lower log P), (ii)
new methods with which to access novel substitution patterns
(improved synthetic tractability), or (iii) that provide access to
new chemical space is of immense importance in the search
for new bioactive agents.
Concurrently, in specific relation to the pharmaceutical
industry, fragment-based drug discovery is of considerable
interest in the search for new ligands for biological targets and
oﬀers an eﬃcient method of identifying new hits or leads.3
New or unusual heterocyclic fragments and derivatives are par-
ticularly valued in this area as they can oﬀer many of the desir-
able attributes described above and provide good points on
which to base further research and development.
As part of a programme aimed at the preparation of
unusual heterocyclic structures, we have targeted the gener-
ation of libraries of novel heteroaromatic scaﬀolds. More
specifically, we have been interested in the 4H-quinolizin-
4-one ring system (Fig. 1) based on calculated desirable
physicochemical properties and projected synthetic utility.4
The 4H-quinolizin-4-one scaﬀold and the related partially- or
fully-saturated systems have previously found broad use within
medicinal chemistry programmes as ligands for a variety of
receptor targets including as treatments for Alzheimer’s
disease,5 Type 2 diabetes,6 and HIV.7 However, despite
encouraging biological activity, there is a lack of a general
method for the construction of this ring system. Existing
methods tend to be bespoke for a particular target and lack
flexibility rendering them unsuitable to the generation of a
bank of analogues. Consequently, we became interested in
pursuing a more general method for the assembly of this
valuable ring system and one that may be amenable to
Fig. 1 The 4H-quinolizin-4-one ring system and proposed tandem HWE/cycli-
sation strategy.
†Electronic supplementary information (ESI) available: Experimental procedures
and characterisation data for all compounds, crystallographic data for com-
pound 3a. CCDC 915082. For ESI and crystallographic data in CIF or other elec-
tronic format see DOI: 10.1039/c3ob40578h
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variation of substitution and functionality in order to improve
synthetic tractability upon identification of a promising
ligand.
Our synthetic strategy is shown in Fig. 1.8 From a suitable
β-carbonyl pyridine, the pyridone ring would be annulated via
a tandem Horner–Wadsworth–Emmons olefination/cyclisation
event with the cyclisation taking place under thermal pro-
motion.9 Use of functionalised β-carbonyl pyridines and/or
phosphonates would potentially provide a range of functional-
ity in the products around the pyridone ring.
We were specifically interested in 2-substituted 4H-quinol-
izin-4-ones as routes to this specific substitution are exceed-
ingly rare with only one example of a direct preparation which
delivers a mixture of products.8k All other previous routes gen-
erate products with 1,2-, 2,3-, or 1,2,3-functionalisation.8
However, in terms of bioactive agents, fine-tuning of the 2-sub-
stitution is key for potency and selectivity.5–7 As such, to
initiate our study we required access to β-ketopyridines of type
1 where R1 and R3 = H and R2 = alkyl or aryl (Fig. 1). A con-
venient method of preparing these compounds was identified
as being via the direct acylation of the 2-picoline anion,
obtained via deprotonation using organolithium reagents (e.g.,
LDA, n-BuLi).10 In the event, we elected to employ n-BuLi as
trial reactions revealed low reactivity with LDA. In addition, we
surveyed three potential acylating agents: acyl chlorides, esters,
and Weinreb amides (Scheme 1). While Weinreb amides were
anticipated to be less problematic in terms of the potential for
over-alkylation, we reasoned that the tetrahedral intermediate
generated upon nucleophilic addition to acyl chlorides or
esters may be stabilised by the presence of the pyridine nitro-
gen (via a 6-membered chelate) and thus may prevent collapse
in the reaction vessel, enabling acylation with these more
readily available (commercial) reagents.11 Indeed, in prelimi-
nary reactions, esters were found to perform equally as well as
Weinreb amides with acyl chlorides revealed as unsuited to
the desired transformation.
However, subsequent optimisation steps demonstrated that
the yields for ester-based acylation were consistently lower
than those achievable using the corresponding Weinreb
amides and as such, we moved forward with the latter as the
acylation reagent of choice, with two equivalents of 2-picoline/
n-BuLi proving optimal (83% yield of 1a). Accordingly, a series
of Weinreb amides, 5a–o, were prepared using either acyl
chlorides or an established i-PrMgCl-based ester amidation
method12 (for full details, see the ESI†) and used to prepare a
range of functionalised β-ketopyridines (Scheme 2).
Pleasingly, the developed acylation conditions operated
eﬀectively for both alkyl and aryl Weinreb amides possessing a
range of functionality in generally high yields with only two
exceptions: the NO2-substituted derivative 1i could not be
induced to follow the desired acylation pathway and, instead,
generated a complex mixture of undesired products presum-
ably through reaction pathways enabled by the NO2 functional-
ity. The OTBS substrate 1m could be isolated but in somewhat
moderate yield due to desilylation of the phenol under the
basic reaction conditions.
It should be noted that β-ketopyridines 1a–o exist as a
mixture of enol–keto tautomers, with the ratio dependent on
the carbonyl substitution. These compounds may find further
use as synthetic intermediates or, based on the proximity of
the heteroatoms, as ligands for metal systems.
With these β-ketopyridines in hand, our attention moved to
the pivotal tandem HWE/cyclisation process. Exposing β-keto-
pyridine 1a to a mixture of triethylphosphonoacetate and NaH
in toluene at 0 °C followed by warming to reflux for 20 h deliv-
ered the 4H-quinolizin-4-one 3a in 31% yield (Scheme 3).
Simply increasing the ratio of triethylphosphonoacetate and
NaH to 2 equivalents delivered 3a in a synthetically useful
yield of 92%. Structural confirmation was achieved by NMR as
well as X-ray crystallography (Scheme 3).
We proceeded to apply these conditions to the range of
β-ketopyridines to provide a small array of 4H-quinolizin-
4-ones in generally good yields (Scheme 4). Once again, the
TBS-protected phenol substrate 3m was isolated in low yieldScheme 1 Evaluation of potential acylating agents.
Scheme 2 Synthesis of β-ketopyridines.
Scheme 3 Tandem synthesis of 4H-quinolizin-4-one 3a from β-ketopyridine
1a. Thermal ellipsoids are drawn at 50% probability.
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due to desilylation under the basic reaction conditions as pre-
viously observed during preparation of the β-ketopyridine 1m.
From a mechanistic perspective, the tandem process pro-
ceeds via HWE olefination of the carbonyl unit followed by
straightforward intramolecular N-acylation of the pyridine,
proton loss, and electronic reorganisation to provide the annu-
lated product. The E/Z selectivity of the HWE olefination
was unknown at this stage although this was assumed to be
E-selective based on the generally high yields of 4H-quinolizin-
4-one product and the assumption that only the E-olefin would
be able to be converted to the annulated product. To validate
this, we decided to probe the selectivity of the olefination by
analysis of an aliquot of the reaction of 1a prior to the reflux
step. We found that the selectivity of the olefination is actually
rather modest at only 4 : 1 in favour of E-2a suggesting a
maximum expected yield of approximately 80%.‡ However, we
observed 100% conversion to 3a suggesting that Z-2a must be
converted to E-2a prior to cyclisation. We believe this is a base-
assisted process proceeding through the enolate 6 which
allows for olefin isomerisation and subsequent cyclisation to
3a (Scheme 5).
Conclusions
In summary, we have developed a tandem Horner–Wads-
worth–Emmons/cyclisation approach for the synthesis of the
4H-quinolizin-4-one architecture. The developed route enables
eﬀective synthesis of 2-substituted 4H-quinolizin-2-ones and
proceeds in good to excellent yield. Based on the highly
eﬀective use of 2-substituted 4H-quinolizin-4-one scaﬀolds
within bioactive agents and the significance of this particular
ring substitution in the context of target potency and selectiv-
ity, we believe this new synthetic approach will be of broad
utility in the design and synthesis of new biologically active
compounds. Translation of this process in order to realise
alternative substitution patterns and novel heterocyclic ring
constructs is currently underway.
Experimental section
General experimental procedure for the deprotonation of
2-picoline and nucleophilic addition to Weinreb amides
For example, for compound 1a. An oven-dried flask equipped
with a stirrer bar and fitted with a septum was purged with N2.
The flask was cooled to −78 °C by submerging in a bath of dry
ice/acetone. The flask was then charged with dry THF (11 mL)
and 2-picoline (2 equiv., 4 mmol, 372.5 mg, 0.395 mL) and
stirred. n-Butyllithium (1.6 M in hexanes, 2 equiv., 4 mmol,
2.5 mL) was added to the flask dropwise over 5 minutes. Con-
currently, an additional oven-dried flask equipped with a
stirrer bar and fitted with a septum was purged with N2. The
flask was cooled to −78 °C by submerging in dry a dry ice/
acetone bath. The flask was then charged with dry THF (5 mL)
and N-methoxy-N-methylbenzamide (1 equiv., 2 mmol,
330.4 mg, 0.304 mL) and stirred. After 30 min, the deproto-
nated picoline solution was added to the Weinreb amide solu-
tion by dropwise addition via syringe over 10 minutes. The
reaction was allowed to proceed for 3 hours before quenching
with water. EtOAc (5 mL) was added and the phases were sep-
arated. The aqueous layer was then re-extracted with EtOAc
(5 × 5 mL). The combined organic phases were dried (MgSO4),
passed through a hydrophobic frit, and concentrated under
reduced pressure to aﬀord a residue that was purified by flash
column chromatography (1 : 2 EtOAc–petroleum ether 40–60°)
to aﬀord the title compound (327 mg, 83% yield).
General experimental procedure for the synthesis of
quinolizinones via tandem Horner–Wadsworth–Emmons
olefination/intramolecular cyclisation
For example, for compound 3a. An oven-dried flask equipped
with stirrer bar was purged with N2 and cooled to 0 °C by sub-
merging in an ice/water bath. The flask was charged with dry
toluene (5 mL), triethyl phosphonoacetate (2 equiv., 2 mmol,
Scheme 4 Tandem HWE/cyclisation 4H-quinolizin-4-one synthesis.
Scheme 5 Proposed mechanism for the tandem reaction.
‡The E : Z ratio was determined by nOe 1H NMR spectroscopy.
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448.4 mg, 0.398 mL), and NaH (60% dispersion in mineral oil,
2 equiv., 2 mmol, 83.0 mg). The mixture was stirred for 15 min
before removing from the cooling bath and warming to room
temperature. 1-Phenyl-2-(pyridin-2-yl)ethanone (1a, 1 equiv.,
1 mmol, 197.1 mg) was added and the reaction mixture was
heated to reflux for 20 hours. The reaction was then treated
with Et2O (5 mL), concentrated under reduced pressure to a
residue that was purified by flash column chromatography
(1 : 1 EtOAc–petroleum ether 40–60°) to aﬀord the title com-
pound (203.5 mg, 92% yield).
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